MY199800A - Genetic regulation of immunoresponse by chromosome interactions - Google Patents

Genetic regulation of immunoresponse by chromosome interactions

Info

Publication number
MY199800A
MY199800A MYPI2020002029A MYPI2020002029A MY199800A MY 199800 A MY199800 A MY 199800A MY PI2020002029 A MYPI2020002029 A MY PI2020002029A MY PI2020002029 A MYPI2020002029 A MY PI2020002029A MY 199800 A MY199800 A MY 199800A
Authority
MY
Malaysia
Prior art keywords
immunoresponse
genetic regulation
chromosome interactions
interactions
chromosome
Prior art date
Application number
MYPI2020002029A
Other languages
English (en)
Inventor
Ewan Hunter
Aroul Selvam Ramadass
Alexandre Akoulitchev
Original Assignee
Oxford BioDynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford BioDynamics PLC filed Critical Oxford BioDynamics PLC
Publication of MY199800A publication Critical patent/MY199800A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2020002029A 2017-11-03 2018-11-02 Genetic regulation of immunoresponse by chromosome interactions MY199800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581287P 2017-11-03 2017-11-03
GB2018052818 2018-10-03
PCT/GB2018/053196 WO2019086898A2 (en) 2017-11-03 2018-11-02 Genetic regulation

Publications (1)

Publication Number Publication Date
MY199800A true MY199800A (en) 2023-11-23

Family

ID=64661410

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002029A MY199800A (en) 2017-11-03 2018-11-02 Genetic regulation of immunoresponse by chromosome interactions

Country Status (13)

Country Link
US (1) US11840737B2 (enExample)
EP (1) EP3704274B1 (enExample)
JP (2) JP2021501592A (enExample)
KR (1) KR102885025B1 (enExample)
CN (1) CN111511930B (enExample)
AU (1) AU2018361833B2 (enExample)
CA (1) CA3078675A1 (enExample)
ES (1) ES2987603T3 (enExample)
HU (1) HUE066292T2 (enExample)
MY (1) MY199800A (enExample)
PL (1) PL3704274T3 (enExample)
SG (1) SG11202003233YA (enExample)
WO (1) WO2019086898A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152645A1 (en) * 2019-09-11 2021-03-18 Oxford BioDynamics PLC Diagnostic chromosome marker
IL296568A (en) * 2020-03-17 2022-11-01 Regeneron Pharma Methods and systems for determining responders to treatment
GB202008269D0 (en) * 2020-06-02 2020-07-15 Oxford Biodynamics Ltd Detecting a chromosome marker
GB202016176D0 (en) * 2020-10-12 2020-11-25 Oxford BioDynamics PLC Disease marker
TW202302862A (zh) * 2021-03-04 2023-01-16 英商牛津生物力學公眾有限公司 染色體交互作用標記物
WO2025215189A1 (en) * 2024-04-12 2025-10-16 Oxford BioDynamics PLC Chromosome marker test

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
GB0603251D0 (en) 2006-02-17 2006-03-29 Isis Innovation DNA conformation
CN101688237A (zh) 2007-01-11 2010-03-31 伊拉兹马斯大学医疗中心 环状染色体构象捕获(4c)
EP2201140A2 (en) 2007-10-15 2010-06-30 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
GB0810051D0 (en) 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
CN102549167B (zh) 2009-05-12 2017-04-26 皇家飞利浦电子股份有限公司 作为前列腺癌标志物的磷酸二酯酶4d7
AU2014275166B2 (en) * 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
WO2015077414A1 (en) 2013-11-20 2015-05-28 Dana-Farber Cancer Institute, Inc. Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response
JP2018527016A (ja) * 2015-06-24 2018-09-20 オックスフォード バイオダイナミックス リミテッド 染色体相互作用の検出

Also Published As

Publication number Publication date
WO2019086898A2 (en) 2019-05-09
JP2021501592A (ja) 2021-01-21
EP3704274B1 (en) 2024-04-17
ES2987603T3 (es) 2024-11-15
CN111511930B (zh) 2024-11-22
AU2018361833B2 (en) 2021-04-22
KR20200081380A (ko) 2020-07-07
AU2018361833A1 (en) 2020-04-30
EP3704274A2 (en) 2020-09-09
JP2023082157A (ja) 2023-06-13
PL3704274T3 (pl) 2024-07-08
SG11202003233YA (en) 2020-05-28
US11840737B2 (en) 2023-12-12
CA3078675A1 (en) 2019-05-09
NZ763540A (en) 2025-03-28
CN111511930A (zh) 2020-08-07
HUE066292T2 (hu) 2024-07-28
US20210230702A1 (en) 2021-07-29
JP7631400B2 (ja) 2025-02-18
WO2019086898A3 (en) 2019-06-13
EP3704274C0 (en) 2024-04-17
KR102885025B1 (ko) 2025-11-11

Similar Documents

Publication Publication Date Title
IL287033A (en) Nuclease-mediated regulation of gene expression
WO2019086898A3 (en) Genetic regulation of immunoresponse by chromosome interactions
MY186113A (en) Epigenetic chromosome interactions
LT3265563T (lt) Genų raiškos reguliavimas aptamerų sąlygotu alternatyvaus splaisingo moduliavimu
GR20140100479A (el) Συνθεση λιραγλουτιδης
CY1125996T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2017010638A (es) Derivados de sobetiroma.
AU2014375265A1 (en) Novel pyrazolyl-heteroarylamides as pesticides
EP3332014A4 (en) METHOD FOR PRODUCING ANIMAL WITH GENETIC GLAND CARBON MODIFICATION
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
MY207247A (en) Detection of chromosome interaction relevant to breast cancer
ECSDI17072111S (es) Recipiente contenedor (iv)
SG10201902813XA (en) Methods and materials for biosynthesis of mogroside compounds
AU2015205241A1 (en) Method for operating blast furnace
IL282752A (en) Methods for altering gene expression for genetic disorders
MX2016014765A (es) Incremento del rendimiento utilizando soforolipidos.
IL268977A (en) Regulation of gene expression by aptamer-modulated rnase p cleavage
PH12020551791A1 (en) Methods for the production of methacrylates
EA201691426A1 (ru) Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков
MY200184A (en) Biomarker
DK3625327T3 (da) Højproduktive fremgangsmåder til methanfermentering
DK3322936T3 (da) Fremgangsmåde til regulering af en forbrændingsproces
JOP20200034A1 (ar) تركيبة للتنشيط المتحكم فيه للمبيض
FR3020274B1 (fr) Ensemble de regulation pour masque respiratoire.
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof